• Policy
• 'Lixiana' patent expires next year, good news for
• by Lee, Hye-Kyung Jan 24, 2025 05:51am

• Policy
• Hokunalin Patch has been removed from Korea’s reimbursement
• by Lee, Tak-Sun Jan 24, 2025 05:51am

• Policy
• Govt plans to expand CDMO capacity by 2.5 times
• by Lee, Hye-Kyung Jan 24, 2025 05:51am

• Policy
• If atrial fibrillation develops, Rx 'Omega-3' API
• by Lee, Hye-Kyung Jan 23, 2025 05:54am

• Policy
• MFDS approves immune thrombocytopenia drug Tavalisse
• by Lee, Hye-Kyung Jan 23, 2025 05:54am

• Policy
• MOHW to 'carefully review' post-dispensing notification law
• by Lee, Jeong-Hwan Jan 22, 2025 05:54am

• Policy
• Yuyu seeks to expand the scope of its fexofenadine to ETC
• by Lee, Tak-Sun Jan 21, 2025 05:54am

• Policy
• CKD completes acquisition of diabetes drug 'Januvia'
• by Lee, Tak-Sun Jan 21, 2025 05:54am

• Policy
• MFDS approves Vyvgart for severe myasthenia gravis
• by Lee, Hye-Kyung Jan 21, 2025 05:54am

• Policy
• MFDS' pharma policy keyword, 'shorten time'
• by Lee, Hye-Kyung Jan 21, 2025 05:54am